Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBIT Margin: 2019-2024

Historic EBIT Margin for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to 146.38%.

  • Silence Therapeutics' EBIT Margin fell 1450319.00% to 16,505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 321.21%, marking a year-over-year increase of 11438.00%. This contributed to the annual value of 146.38% for FY2024, which is 5709.00% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' EBIT Margin is 146.38%, which was up 28.06% from 203.47% recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' EBIT Margin peaked at 146.38% during FY2024, and registered a low of 654.26% during FY2020.
  • In the last 3 years, Silence Therapeutics' EBIT Margin had a median value of 203.47% in 2023 and averaged 210.57%.
  • As far as peak fluctuations go, Silence Therapeutics' EBIT Margin surged by 866,295bps in 2020, and later crashed by 5,709bps in 2024.
  • Silence Therapeutics' EBIT Margin (MRY) stood at 654.26% in 2020, then skyrocketed by 44bps to 369.02% in 2021, then increased by 24bps to 281.87% in 2022, then rose by 28bps to 203.47% in 2023, then grew by 28bps to 146.38% in 2024.
  • Its EBIT Margin stands at 146.38% for FY2024, versus 203.47% for FY2023 and 281.87% for FY2022.